Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
24 recruiting
Showing 1–20 of 38 trials
Recruiting
Phase 4
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Amgen300 enrolled80 locationsNCT06072482
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.737 enrolled143 locationsNCT05254743
Recruiting
Phase 3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Metastatic CancerAdvanced Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.482 enrolled126 locationsNCT05208047
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled204 locationsNCT05797610
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled332 locationsNCT07028853
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled290 locationsNCT06252649
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Migraine
Pfizer200 enrolled103 locationsNCT06616194
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
Celgene200 enrolled54 locationsNCT06782490
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 2Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC201 enrolled115 locationsNCT05327114
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC380 enrolled70 locationsNCT07230691
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC641 enrolled193 locationsNCT06319820
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled270 locationsNCT05552222
Recruiting
Phase 3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled186 locationsNCT07276399
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche120 enrolled93 locationsNCT05503264
Recruiting
Phase 2
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled74 locationsNCT05963074
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled311 locationsNCT07063745
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled250 locationsNCT06852222
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled140 locationsNCT06615479
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled752 locationsNCT07157774